

# CITATION REPORT

List of articles citing

## Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus

DOI: 10.1002/oby.22748  
Obesity, 2020, 28, 724-732.

**Source:** <https://exaly.com/paper-pdf/76983165/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. <i>Journal of Biological Chemistry</i> , <b>2020</b> , 295, 14379-14390	5.4	19
8	SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type2 Diabetes: A Narrative Review. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 2249-2261	3.6	3
7	Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. <i>Current Obesity Reports</i> , <b>2021</b> , 10, 14-30	8.4	31
6	Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. <i>Endocrine Reviews</i> , <b>2021</b> ,	27.2	4
5	Review of pharmaceutical and therapeutic approaches for type 2 diabetes and related disorders.. <i>Recent Patents on Biotechnology</i> , <b>2022</b> ,	2.2	
4	Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 752440	5.6	0
3	Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: A case series.		0
2	Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms.. <b>2023</b> , 106667		0
1	Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type2 Diabetes and Overweight or Obesity. <b>2023</b> , 14, 319-334		0